<DOC>
	<DOC>NCT00485459</DOC>
	<brief_summary>The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.</brief_summary>
	<brief_title>Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Subject must have ADHD that meet DSMIV disease diagnostic criteria as well as severity criteria Subjects must be aged 6 to 16 years Subjects must not have taken any medication used to treat ADHD or they must have completed the washout procedures Subjects must be able to swallow capsules Subjects must be of normal intelligence in the judgment of the investigator. Normal intelligence is defined as being without evidence of significant general intellectual deficit and expected to achieve a score of 80 or more if formal IQ testing were administered. Weigh less than 20 kg or more than 60 kg at study entry Have a history of Bipolar I or II disorder, psychosis, or pervasive developmental disorder Meet DSMIV criteria for an anxiety disorder as assessed by the investigator Have a history of any seizure disorder (other than febrile seizures) or prior ECG abnormalities related to epilepsy, or subjects who have taken (or are currently taking) anticonvulsants for seizure control Subjects who have a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>